BioNexus Gene Lab (BGLC) Short-term Investments (2020 - 2026)

BioNexus Gene Lab has reported Short-term Investments for 5 years, with the latest figure at $2.6 million in Q1 2026.

• Quarterly Short-term Investments changed N/A year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (changed N/A YoY) and the FY2025 annual result came in at $1.7 million, down 40.72% from the prior year.
• Short-term Investments rose to $2.6 million in Q1 2026 per BGLC's latest filing, from $1.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $2.8 million in Q4 2024 and troughed at $1.7 million in Q4 2025.
• A 3-year average of $2.2 million and a median of $2.2 million in 2025 frame the typical range for Short-term Investments.
• The widest YoY moves for Short-term Investments: up 40.72% in 2025, down 40.72% in 2025.
• Over 3 years, Short-term Investments stood at $2.8 million in 2024, then sank by 40.72% to $1.7 million in 2025, then soared by 58.63% to $2.6 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $2.6 million, $1.7 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.